Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7059298 | 0.85 | SCN10A (0.66) | SCN10ASCN2ASCN9ASCN3APTK2 | |
| SCHEMBL2415714 | 0.81 | SCN10A (0.53) | SCN10AMAPTSMN1; SMN2JAK2NTRK1 | |
| SCHEMBL2414888 | 0.81 | SCN10A (0.55) | SCN10ASCN2ASCN9ASCN3ASLC9A1 | |
| SCHEMBL2415628 | 0.81 | SCN10A (0.73) | SCN10ASCN9AMAPTJAK2NTRK1 | |
| SCHEMBL2414024 | 0.81 | SCN10A (0.55) | SCN10ASLC9A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL7108417 | 0.80 | ABL1 (0.48) | SCN10ASCN2ASCN9ASCN3APTK2 | |
| SCHEMBL2416392 | 0.80 | ALOX15 (0.55) | SCN10AMAPTDYRK1ASMN1; SMN2LMNA | |
| SCHEMBL2416391 | 0.80 | SCN10A (0.52) | SCN10AKDM4EMAPTJAK2NTRK1 | |
| SCHEMBL2411147 | 0.80 | SCN10A (0.79) | SCN10ASCN2ASCN9ASCN3AMAPT | |
| SCHEMBL2421416 | 0.76 | NPC1 (0.45) | SCN10ASCN9AMAPTSMN1; SMN2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966448-B1 | PYRAZINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-6599905-B2 | Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-29 | — | — | US | disclosed |
| US-20020169172-A1 | Pyrazine compounds | GLAXO WELLCOME INC. | 2002-11-14 | — | — | US | disclosed |
| US-6255307-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | GLAXO WELLCOME, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0966448-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038174-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169172-A1 | Pyrazine compounds | HCRTR1, HCRTR2, GRIN2C | SCN10A 320/4885SCN2A 92/4885SCN9A 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.